<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639261</url>
  </required_header>
  <id_info>
    <org_study_id>IFN_BOSZT_01</org_study_id>
    <secondary_id>2010-022467-36</secondary_id>
    <nct_id>NCT01639261</nct_id>
  </id_info>
  <brief_title>A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT</brief_title>
  <acronym>IFN_BOSZT_01</acronym>
  <official_title>Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement of quality of life in patients with BO and establishment of a new third line&#xD;
      therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      Objective improvement of lung function, i.e.:&#xD;
&#xD;
        -  Improvement of SO2, pO2 or pCO2 in oxygen dependent or improvement of FiO2 in&#xD;
           respiration dependent patients ≥ 20 % or&#xD;
&#xD;
        -  Reduction of oxygen need in oxygen dependent patients ≥ 1L O2/min with constant&#xD;
           parameters at blood gas analysis (BGA) or&#xD;
&#xD;
        -  Improvement of obstructive parameters ≥ 20 % or&#xD;
&#xD;
        -  Improvement of lung function score (LFS) at least about one grade Improvement of lung&#xD;
           function should be detectable at least by two consecutive examinations of lung function&#xD;
           or BGA within at least four weeks.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  Morphological improvement of BO/BOOP at CT scan&#xD;
&#xD;
        -  Reduction of steroids about at least 20 %&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>therapy response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Enhancement of therapy response from 15 % to 50 %</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Steroid-refractory Bronchiolitis Obliterans</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon gamma 1b</intervention_name>
    <description>Initial dose: 50µg s.c. three times/week, without fever &gt;38,5 dose increase: 50µg/m² BSA three times/week</description>
    <other_name>Imukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Allogeneic SCT&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  BO, firmed by 2 out of 3 examinations:&#xD;
&#xD;
               -  Lung function/ BGA&#xD;
&#xD;
               -  CT scan in in- and expiration or&#xD;
&#xD;
               -  Histological diagnosis&#xD;
&#xD;
          -  Therapy refractory BO, i.e. no improvement during at least three therapies, among:&#xD;
&#xD;
               -  Azithromycin + inhaled steroids/ bronchodilators&#xD;
&#xD;
               -  Systemic steroids 1 mg/kg BW&#xD;
&#xD;
               -  One of the following therapies: MMF, mTOR inhibitors or ECP&#xD;
&#xD;
          -  Effective contraception (before, during and for 8 weeks after the treatment)&#xD;
&#xD;
          -  Blood count: no severe neutropenia, defined as ANC &gt; 1000/ml, platelets &gt; 50/nl and&#xD;
             haemoglobin &gt; 8 g/dl&#xD;
&#xD;
          -  Liver parameters (bilirubin, gammaGT, AP, ASAT, ALAT) lower than 3 x paramount normal&#xD;
             range&#xD;
&#xD;
          -  Kreatinin lower than 3 x paramount normal range&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnant or nursing woman&#xD;
&#xD;
          -  No appropriate contraception&#xD;
&#xD;
          -  Participation in any other study within 4 weeks before or during the study&#xD;
&#xD;
          -  Active acute GvHD of other organs than the lung &gt; grade II or severe active chronic&#xD;
             GvHD&#xD;
&#xD;
          -  No appropriate antibiotic/ antimycotic therapy in documented infection&#xD;
&#xD;
          -  Severe bone marrow suppression (ANC &lt; 1000/ml) or graft failure&#xD;
&#xD;
          -  Liver parameters (bilirubin, gammaGT, AP, ASAT and ALAT) higher than 3 x paramount&#xD;
             normal range&#xD;
&#xD;
          -  Kreatinin higher than 3 x paramount normal range&#xD;
&#xD;
          -  Participation in another study within 4 weeks before or during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst Holler, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Regensburg</investigator_affiliation>
    <investigator_full_name>Professor Ernst Holler MD</investigator_full_name>
    <investigator_title>Senior physician</investigator_title>
  </responsible_party>
  <keyword>steroid-refractory</keyword>
  <keyword>bronchiolitis obliterans</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>interferon gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

